Research Paper Volume 13, Issue 8 pp 11988—12006
High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia
- 1 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- 2 Department of Hematology, People’s Hospital Affiliated to Ningbo University, Ningbo 315000, China
- 3 Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- 4 Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou 310003, China
- 5 Department of Hematology, Jinshan Hospital of Fudan University, Shanghai 201500, China
- 6 Shanghai Tissuebank Biotechnology Co., Ltd, Shanghai 201318, China
Received: November 6, 2020 Accepted: March 14, 2021 Published: April 23, 2021https://doi.org/10.18632/aging.202901
How to Cite
Copyright: © 2021 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Acute myeloid leukemia (AML) is a frequent malignancy in adults worldwide; identifying preferable biomarkers has become one of the current challenges. Given that COMMD7 has been reported associated with tumor progression in various human solid cancers but rarely reported in AML, herein, RNA sequencing data from TCGA and GTEx were obtained for analysis of COMMD7 expression and differentially expressed gene (DEG). Furthermore, functional enrichment analysis of COMMD7-related DEGs was performed by GO/KEGG, GSEA, immune cell infiltration analysis, and protein-protein interaction (PPI) network. In addition, the clinical significance of COMMD7 in AML was figured out by Kaplan-Meier Cox regression and prognostic nomogram model. R package was used to analyze incorporated studies. As a result, COMMD7 was highly expressed in various malignancies, including AML, compared with normal samples. Moreover, high expression of COMMD7 was associated with poor prognosis in 151 AML samples, as well as subgroups with age >60, NPM1 mutation-positive, FLT3 mutation-negative, and DNMT3A mutation-negative, et al. (P < 0.05). High COMMD7 was an independent prognostic factor in Cox regression analysis; Age and cytogenetics risk were included in the nomogram prognostic model. Furthermore, a total of 529 DEGs were identified between the high- and the low- expression group, of which 92 genes were up-regulated and 437 genes were down-regulated. Collectively, high expression of COMMD7 is a potential biomarker for adverse outcomes in AML. The DEGs and pathways recognized in the study provide a preliminary grasp of the underlying molecular mechanisms of AML carcinogenesis and progression.
AML: acute myeloid leukemia; COMMD7: COMM domain-containing protein 7; TCGA: the cancer genome atlas; GTEx: Genotype-Tissue Expression; DEGs: Differentially Expressed Genes; GSEA: Gene set enrichment analysis; ssGSEA: single-sample Gene Set Enrichment Analysis; GO: Gene Ontology; CC: cellular component; MF: molecular function; BP: biological process; KEGG: Kyoto Encyclopedia of Genes and Genomes; STRING: Search Tool for the Retrieval of Interacting Genes; PPI: Protein-protein interaction; ROC: receiver operating characteristic; AUC: area under the curve.